The University of Southampton
University of Southampton Institutional Repository

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
Purpose: an open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma.
Patients and methods: a single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 109/L). Forty of 41 patients received both infusions.
Results: thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient.
Conclusion: high overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed
1527-7755
1469-1479
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Rohatiner, A.Z.S.
d5f8f82b-7677-4483-8653-42b96a2648f8
Howell, S.
12318b46-6678-4e56-a9d2-c1f4bf7e126a
Britton, K.E.
1d94bbb6-880b-4b52-b5ab-e5015c67f569
Owens, S.E.
0a6ffc18-e5db-408a-b481-176b64e78e87
Micallef, I.N.
f37b18a5-a105-48c0-a644-59bc1e308370
Deakin, D.P.
fbc551a7-475c-4cd6-bd44-0c95e459ac70
Carrington, B.M.
0f562f25-9c2d-43cf-b5cc-56538e89f405
Lawrance, J.A.
ddb2a09a-65db-4041-b57a-5258883530d3
Vinnicombe, S.
76f44048-c7f0-4a79-968c-41d7ece30e6b
Mather, S.J.
70ae20f1-69d3-4f66-8ee3-72d6e7d0fb9d
Clayton, J.
d02bf02b-5fbb-4f09-b88c-f94a19575537
Foley, R.
121aa565-0080-4c5f-bea1-2b47bb348e19
Jan, H.
e87c134b-b5d7-48e9-bce3-58afd7bdf834
Kroll, S.
daf450b6-6cb9-41a5-86de-b65111625da8
Harris, M.
b0e2d8cb-44f8-47a5-8e1b-6ca9c04fe776
Amess, J.
71bf8bdf-5591-4bde-871f-412789768219
Norton, A.J.
fe7d8253-bcfa-4789-9397-4001b795d75c
Lister, T.A.
ffe041c9-eb11-47e8-8c7c-177f8bc193c9
Radford, J.A.
77dd6342-413d-47e4-8c72-1b7829efba99
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Rohatiner, A.Z.S.
d5f8f82b-7677-4483-8653-42b96a2648f8
Howell, S.
12318b46-6678-4e56-a9d2-c1f4bf7e126a
Britton, K.E.
1d94bbb6-880b-4b52-b5ab-e5015c67f569
Owens, S.E.
0a6ffc18-e5db-408a-b481-176b64e78e87
Micallef, I.N.
f37b18a5-a105-48c0-a644-59bc1e308370
Deakin, D.P.
fbc551a7-475c-4cd6-bd44-0c95e459ac70
Carrington, B.M.
0f562f25-9c2d-43cf-b5cc-56538e89f405
Lawrance, J.A.
ddb2a09a-65db-4041-b57a-5258883530d3
Vinnicombe, S.
76f44048-c7f0-4a79-968c-41d7ece30e6b
Mather, S.J.
70ae20f1-69d3-4f66-8ee3-72d6e7d0fb9d
Clayton, J.
d02bf02b-5fbb-4f09-b88c-f94a19575537
Foley, R.
121aa565-0080-4c5f-bea1-2b47bb348e19
Jan, H.
e87c134b-b5d7-48e9-bce3-58afd7bdf834
Kroll, S.
daf450b6-6cb9-41a5-86de-b65111625da8
Harris, M.
b0e2d8cb-44f8-47a5-8e1b-6ca9c04fe776
Amess, J.
71bf8bdf-5591-4bde-871f-412789768219
Norton, A.J.
fe7d8253-bcfa-4789-9397-4001b795d75c
Lister, T.A.
ffe041c9-eb11-47e8-8c7c-177f8bc193c9
Radford, J.A.
77dd6342-413d-47e4-8c72-1b7829efba99

Davies, A.J., Rohatiner, A.Z.S., Howell, S., Britton, K.E., Owens, S.E., Micallef, I.N., Deakin, D.P., Carrington, B.M., Lawrance, J.A., Vinnicombe, S., Mather, S.J., Clayton, J., Foley, R., Jan, H., Kroll, S., Harris, M., Amess, J., Norton, A.J., Lister, T.A. and Radford, J.A. (2004) Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 22 (8), 1469-1479. (doi:10.1200/JCO.2004.06.055).

Record type: Article

Abstract

Purpose: an open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma.
Patients and methods: a single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 109/L). Forty of 41 patients received both infusions.
Results: thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient.
Conclusion: high overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed

Full text not available from this repository.

More information

Published date: 15 April 2004

Identifiers

Local EPrints ID: 73347
URI: https://eprints.soton.ac.uk/id/eprint/73347
ISSN: 1527-7755
PURE UUID: a9bd6f81-b5f4-4147-8b7c-94953445781e

Catalogue record

Date deposited: 05 Mar 2010
Last modified: 19 Jul 2019 23:41

Export record

Altmetrics

Contributors

Author: A.J. Davies
Author: A.Z.S. Rohatiner
Author: S. Howell
Author: K.E. Britton
Author: S.E. Owens
Author: I.N. Micallef
Author: D.P. Deakin
Author: B.M. Carrington
Author: J.A. Lawrance
Author: S. Vinnicombe
Author: S.J. Mather
Author: J. Clayton
Author: R. Foley
Author: H. Jan
Author: S. Kroll
Author: M. Harris
Author: J. Amess
Author: A.J. Norton
Author: T.A. Lister
Author: J.A. Radford

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×